The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | ASCO 2024: key updates in gastric, colorectal, and hepatocellular cancer treatments
Ian Chau, MD, from Royal Marsden Hospital in London, UK, anticipates key presentations at ASCO 2024, particularly comparing preoperative chemoradiation to therapeutic chemotherapy in resectable gastric cancer, resolving a longstanding debate. Additionally, he looks forward to data on dual checkpoint therapy versus ipilimumab plus nivolumab in colorectal cancer and hepatocellular carcinoma, which promises insights into novel treatment approaches. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Bristol-Myers Squibb; Eisai; Lilly; Novartis; Roche/Genentech; SERVIER
Consulting or Advisory Role – Astellas Pharma; AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding – Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses – BMS; SERVIER
